SenGenix Inc. brings an experienced management team that is developing point-of-care diagnostic tests (POCT) based on fluorescently responsive sensors (FRS) that will deliver fast, accurate, actionable patient data at a low cost. The Company will commercialize protein-engineering technologies developed at Duke University Medical Center to create a product platform that will be designed to perform a menu of tests at the point-of-care. The product roll-out strategy over the next five years includes a stand-alone Creatinine test, and a Basic Metabolic Panel (BMP) consisting of the eight most commonly ordered tests (Glucose, BUN, Creatinine, Sodium, Potassium, Calcium, Chloride and Bicarbonate). These will provide clinicians with highly accurate results to assess patients at the location where care is required and within a time frame during which clinical decisions are most effective.